Image_2_Emerging innovations on exosome-based onco-therapeutics.tif

Exosomes, nano-sized extracellular vesicles for intercellular communications, are gaining rapid momentum as a novel strategy for the diagnosis and therapeutics of a spectrum of diseases including cancers. Secreted by various cell sources, exosomes pertain numerous functionalities from their parental cells and have enhanced stability that enable them with many features favorable for clinical use and commercialization. This paper focuses on the possible roles of exosomes in cancer therapeutics and reviews current exosome-based innovations toward enhanced cancer management and challenges that limit their clinical translation. Importantly, this paper casts insights on how cold atmospheric plasma, an emerging anticancer strategy, may aid in innovations on exosome-based onco-therapeutics toward improved control over cancers.</p

Image_1_Emerging innovations on exosome-based onco-therapeutics.tif

Exosomes, nano-sized extracellular vesicles for intercellular communications, are gaining rapid momentum as a novel strategy for the diagnosis and therapeutics of a spectrum of diseases including cancers. Secreted by various cell sources, exosomes pertain numerous functionalities from their parental cells and have enhanced stability that enable them with many features favorable for clinical use and commercialization. This paper focuses on the possible roles of exosomes in cancer therapeutics and reviews current exosome-based innovations toward enhanced cancer management and challenges that limit their clinical translation. Importantly, this paper casts insights on how cold atmospheric plasma, an emerging anticancer strategy, may aid in innovations on exosome-based onco-therapeutics toward improved control over cancers.</p

Additional file 11 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Additional file 11: Supplementary Table 11. Protein-protein interactions among genes differentially correlated with SNRPD1 and SNRPE. Protein-protein interactions were constructed using STRING

Additional file 1 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Additional file 1: Supplementary Table 1. Data sets description for computational prediction at the mRNA and genetic levels. In eQTL analysis, the number of samples overlapping among different types of data and used in the analysis is shown in 'Overlap'. In GEX survival (gene expression association analysis) and SNP survival (association analysis at the genetic level), the sample sizes are shown with the number of events listed in the brackets

Additional file 10 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Additional file 10: Supplementary Table 10. Genes differentially correlated with SNRPD1 and SNRPE using both TCGA gene expression and MS protein expression data

Additional file 12 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Additional file 12: Supplementary Figure 1. Work flow and logic of this study. This study is comprised of investigations on the ‘phenomenon’ of SNRPD1 and SNRPE relevant to breast cancer prognosis and therapeutics, and ‘mechanism’ capable of explaining the observed phenomenon. In each set of investigations, both in silico dry lab analysis and in vitro wet lab experiments were conducted. ‘Green’ and ‘purple’ each represents dry lab analysis and wet lab assays conducted for SNRPD1 and SNRPE, respectively. ‘Black’ represents the analysis or assays. Statements in the brackets are conclusions drawn on SNRPD1 (‘green’) or SNRPE (‘purple’) from the corresponding series of analysis or experiments

Additional file 2 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Additional file 2: Supplementary Table 2. Information on siRNAs purchased for knocking down SNRPD1 and SNRPE and main reagents used in the study

Additional file 5 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Additional file 5: Supplementary Table 5. Information on all antibodies used in the experiments

Additional file 4 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Additional file 4: Supplementary Table 4. Information on the qPCR primers used in the experiments

Additional file 14 of SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity

Additional file 14: Supplementary Figure 3. The efficiency of over-expressing SNRPD1 or SNRPE in MDAMB231 and MCF7 cells. (A) Over-expressing SNRPD1 or (B) SNRPE as tested at the mRNA level. (C) Over-expressing SNRPD1 or (D) SNRPE as tested at the protein level